In an effort to increase patient awareness of the ATTAC II Study, which is an NCI funded, investigator initiated clinical trial, Immunomic attended the Congress of Neurosurgeons Annual Meeting in Boston to gather key industry leaders for information sharing, and distribute communications about the patient travel fund. To increase enrollment for this clinical study, Immunomic Therapeutics has set up a travel fund to support patients with GBM from sites outside of U.F., Orlando Health and Duke’s typical enrollment geography.
Immunomic sponsored a key industry leader dinner at a local restaurant in Boston to discuss Glioblastoma therapies. Eleven MDs from institutions like Harvard, Sloan Kettering, Duke, Emory, Georgetown, UNC, and Wake Forest were in attendance. Drs. Sampson and Mitchell provided an overview of the clinical trials and Dr. Hearl presented information about Immunomic Therapeutics. The videos below offer a view into their perspectives on this important topic.